A Phase 1, Open-Label, Extension Study of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)
Latest Information Update: 14 Mar 2022
At a glance
- Drugs Eramkafusp-alfa (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Spectrum Pharmaceuticals
- 23 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 07 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2025.
- 07 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jul 2025.